Carvedilol Phosphate Capsule, Extended Release
Product Images NDC 71335-0308

7 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Carvedilol Phosphate (NDC 71335-0308). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Carvedilol 1)

Structure (Carvedilol 1)
Chemical structure of carvedilol phosphate, showing the detailed molecular arrangement including aromatic rings, nitrogen, oxygen atoms, and phosphate and water components indicated as H3PO4 and 1/2 H2O.*
FDA Label Image

Figure-1 (Carvedilol Figure1)

Figure-1 (Carvedilol Figure1)
A line graph comparing mortality percentages over 24 months between groups labeled 'Placebo' and 'Carvedilol'. The y-axis indicates percent mortality from 0 to 30, and the x-axis shows time in months from 0 to 24. The graph illustrates lower mortality for the Carvedilol group compared to Placebo, with a statistical significance value indicated as P = 0.0014.*
FDA Label Image

Figure-2 (Carvedilol Spl Figure 2)

Figure-2 (Carvedilol Spl Figure 2)
A forest plot displaying hazard ratios with confidence intervals for different subgroups including men, women, age groups, race, diabetic status, ischemic status, heart rate levels, systolic blood pressure levels, and spironolactone use, concluding with all patients. The x-axis is labeled 'Hazard Ratio' ranging from 0.0 to 2.0 with a vertical line at 1.0 indicating no effect.*
FDA Label Image

Figure-3 (Carvedilol Figure3)

Figure-3 (Carvedilol Figure3)
A line graph showing percent mortality on the vertical axis and months on the horizontal axis, comparing mortality rates between Carvedilol and placebo groups over a 24-month period. The graph indicates lower mortality in the Carvedilol group, with a statistical significance noted (P = 0.03).*
FDA Label Image

Figure-4 (Carvedilol Spl Figure 4)

Figure-4 (Carvedilol Spl Figure 4)
A forest plot showing hazard ratios with 95% confidence intervals for various subgroups in a clinical study. Subgroups include age, gender, timing post myocardial infarction (MI), prior beta-blocker use, Killip class, thrombolytic use, PTCA for MI, history of congestive heart failure, diuretic use during MI, angina, hypertension, diabetes, heart rate, and systolic blood pressure. Horizontal error bars illustrate the hazard ratio range around a central point estimate for each subgroup.*
FDA Label Image

Figure (Carvedilol 2)

Figure (Carvedilol 2)
Two line graphs showing the change in systolic blood pressure (SBP) and diastolic blood pressure (DBP) over 24 hours after a morning dose of carvedilol phosphate extended-release capsules in 20 mg, 40 mg, and 80 mg strengths. The graphs depict time on the x-axis and blood pressure change on the y-axis, with smoothed lines for each dosage level.*
FDA Label Image

Label (Lbl713350308)

Label (Lbl713350308)
Label for Carvedilol Phosphate Extended-Release Capsules 10 mg, repackaged by Bryant Ranch Prepack and manufactured by Frontida BioPharm. The label includes the NDC 71335-0308-1, package size of 30 capsules, storage instructions at 25°C (77°F), and warnings about membrane seal integrity and overdose emergency guidance.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.